Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
954 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,459 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01468324 |
| AZD7451 for Recurrent Gliomas |
| completed |
| Phase 1 |
| 14 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Dec 17, 2019 |
| clinicaltrials |
| NCT01316809 | AZD8055 for Adults With Recurrent Gliomas | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT02893137 | Enhancing Optune Therapy With Targeted Craniectomy | completed | Phase 1 | 15 | Aarhus University HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | withdrawn | Phase 1 / Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT01392209 | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | terminated | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 5 | Nov 22, 2019 | clinicaltrials |
| NCT01654497 | Dexanabinol in Patients With Brain Cancer | completed | Phase 1 | 26 | Santosh Kesari, M.D., Ph.D.OTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT00004853 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00049127 | Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor | completed | Phase 1 / Phase 2 | 64 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02017249 | Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme(ArginineGBM) | completed | Phase 1 | 1 | Inova Health Care ServicesOTHER | 1 | Sep 16, 2019 | clinicaltrials |
| NCT01065805 | A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma | terminated | Phase 1 / Phase 2 | 94 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT02045368 | Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | completed | Phase 1 | 92 | IGF Oncology, LLCINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01454596 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02364206 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma(GLYRad) | completed | Phase 1 / Phase 2 | 18 | Centre Jean PerrinOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)(PARADIGMA) | withdrawn | Phase 1 | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | terminated | Phase 1 | 1 | New York State Psychiatric InstituteOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | completed | Phase 1 / Phase 2 | 54 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jul 31, 2019 | clinicaltrials |
| NCT02202993 | TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM | completed | Phase 1 | 18 | Cavion, Inc.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma(STALLONe) | completed | Phase 1 | 5 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03392545 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)(InSituVac1) | unknown | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT04004975 | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | unknown | Phase 1 / Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme(Dendr2) | terminated | Phase 1 | 26 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 0 | Jul 1, 2019 | clinicaltrials |
| NCT02337426 | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 12 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT01601184 | Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | terminated | Phase 1 / Phase 2 | 24 | Centre Leon BerardOTHER | 4 | May 21, 2019 | clinicaltrials |
| NCT02008877 | SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | completed | Phase 1 / Phase 2 | 20 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01313936 | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | completed | Phase 1 | 32 | University of California, San FranciscoOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM(HERT-GBM) | completed | Phase 1 | 16 | Baylor College of MedicineOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT01688401 | Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). | completed | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | terminated | Phase 1 / Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01644773 | Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) | completed | Phase 1 | 36 | St. Jude Children's Research HospitalOTHER | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03101579 | Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer | completed | Phase 1 | 13 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02189109 | The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma(GBM) | completed | Phase 1 | 11 | NuvOx LLCINDUSTRY | 1 | Feb 28, 2019 | clinicaltrials |
| NCT03687034 | A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma | unknown | Phase 1 | 21 | Leaf Vertical Inc.INDUSTRY | 0 | Feb 26, 2019 | clinicaltrials |
| NCT00977431 | Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform | completed | Phase 1 | 36 | Boehringer IngelheimINDUSTRY | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02173093 | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | unknown | Phase 1 / Phase 2 | 40 | University of VirginiaOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01576692 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 1 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | terminated | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 8, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Dec 17, 2019source: clinicaltrials